What do we really know about treating refractory ventricular fibrillation?

In this episode, we talk to Sheldon Cheskes about the evolving science of cardiac arrest, with a focus on refractory and recurrent ventricular fibrillation. We explore the evidence behind double sequential external defibrillation (DSED), how it compares to standard defibrillation, and what the DOSE VF trial has changed in practice.

This is not just about adding another shock.

We also discuss:

The difference between refractory and recurrent VF — and why it matters

What DSED and vector change actually do in physiological terms

Why guidelines have been slow to move despite emerging evidence

The role of antiarrhythmics, adrenaline, and sequence of care

Practical considerations for introducing DSED into real systems

What comes next — from smarter detection to post-arrest recovery

This is a conversation grounded in real-world resuscitation.

Refractory VF (persistent after multiple shocks) and recurrent VF (returns after ROSC) are distinct clinical problems with different implications

Double sequential external defibrillation (DSED) may improve outcomes in refractory VF by altering current pathways and myocardial depolarisation

Timing matters — waiting too long to escalate may reduce the chance of success

Current guidelines remain cautious, reflecting the balance between evidence and implementation risk

Defibrillation strategy is only one part of a complex system that includes high-quality CPR, drug therapy, and post-resuscitation care

Cardiac arrest survival remains low.

Small improvements in early resuscitation can have large system-wide effects.

Learning from podcasts?

If podcasts form part of your CPD, you can log your listening time across all podcasts on MedPod Learn — not just St Emlyn’s — and generate structured reflection.

The app is free to download, includes a one-month free trial, and offers globally adjusted pricing. If you are already listening, you may as well make it count.